Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H19N3O5S.3H2O |
| Molecular Weight | 419.45 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C3=CC=C(O)C=C3)C(O)=O
InChI
InChIKey=MQXQVCLAUDMCEF-CWLIKTDRSA-N
InChI=1S/C16H19N3O5S.3H2O/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7;;;/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24);3*1H2/t9-,10-,11+,14-;;;/m1.../s1
| Molecular Formula | C16H19N3O5S |
| Molecular Weight | 365.404 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Amoxicillin is one of the widely prescribed antibacterial agents, which was discovered by scientists at Beecham Research Laboratories in 1972. In the US GlaxoSmithKline markets it under the original brand name Amoxil. It is the first line treatment for middle ear infections. It is also used for strep throat, pneumonia, skin infections, and urinary tract infections it is taken by mouth. Amoxicillin inhibits the third and final stage of bacterial cell wall synthesis by preferentially binding to specific penicillin-binding proteins (PBPs) that are located inside the bacterial cell wall. This results in a formation of defective cell wall and a cell death. Common side effects include nausea and rash. It may also increase the risk of yeast infections and, when used in combination with clavulanic acid, diarrhea. It should not be used in those who are allergic to penicillin.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2354204 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | AMOXIL Approved UseAMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. Launch Date3.40934394E11 |
|||
| Curative | AMOXIL Approved UseAMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. Launch Date3.40934394E11 |
|||
| Curative | AMOXIL Approved UseAMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. Launch Date3.40934394E11 |
|||
| Curative | AMOXIL Approved UseAMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. Launch Date3.40934394E11 |
|||
| Curative | AMOXIL Approved UseAMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. Launch Date3.40934394E11 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
11.8 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/836010/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMOXICILLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
37.6 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/836010/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMOXICILLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/836010/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMOXICILLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
775 mg 1 times / day steady, oral Dose: 775 mg, 1 times / day Route: oral Route: steady Dose: 775 mg, 1 times / day Sources: |
unhealthy, > 12 years n = 302 Health Status: unhealthy Condition: pharyngitis secondary to Streptococcus pyogenes Age Group: > 12 years Population Size: 302 Sources: |
Disc. AE: Pharyngolaryngeal pain... Other AEs: Nausea, Pharyngotonsillitis... AEs leading to discontinuation/dose reduction: Pharyngolaryngeal pain (severe, 0.6%) Other AEs:Nausea (1.5%) Sources: Pharyngotonsillitis (0.9%) Vulvovaginal candidiasis (0.9%) Headache (0.7%) Diarrhea (0.5%) Abdominal pain (0.5%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Abdominal pain | 0.5% | 775 mg 1 times / day steady, oral Dose: 775 mg, 1 times / day Route: oral Route: steady Dose: 775 mg, 1 times / day Sources: |
unhealthy, > 12 years n = 302 Health Status: unhealthy Condition: pharyngitis secondary to Streptococcus pyogenes Age Group: > 12 years Population Size: 302 Sources: |
| Diarrhea | 0.5% | 775 mg 1 times / day steady, oral Dose: 775 mg, 1 times / day Route: oral Route: steady Dose: 775 mg, 1 times / day Sources: |
unhealthy, > 12 years n = 302 Health Status: unhealthy Condition: pharyngitis secondary to Streptococcus pyogenes Age Group: > 12 years Population Size: 302 Sources: |
| Headache | 0.7% | 775 mg 1 times / day steady, oral Dose: 775 mg, 1 times / day Route: oral Route: steady Dose: 775 mg, 1 times / day Sources: |
unhealthy, > 12 years n = 302 Health Status: unhealthy Condition: pharyngitis secondary to Streptococcus pyogenes Age Group: > 12 years Population Size: 302 Sources: |
| Pharyngotonsillitis | 0.9% | 775 mg 1 times / day steady, oral Dose: 775 mg, 1 times / day Route: oral Route: steady Dose: 775 mg, 1 times / day Sources: |
unhealthy, > 12 years n = 302 Health Status: unhealthy Condition: pharyngitis secondary to Streptococcus pyogenes Age Group: > 12 years Population Size: 302 Sources: |
| Vulvovaginal candidiasis | 0.9% | 775 mg 1 times / day steady, oral Dose: 775 mg, 1 times / day Route: oral Route: steady Dose: 775 mg, 1 times / day Sources: |
unhealthy, > 12 years n = 302 Health Status: unhealthy Condition: pharyngitis secondary to Streptococcus pyogenes Age Group: > 12 years Population Size: 302 Sources: |
| Nausea | 1.5% | 775 mg 1 times / day steady, oral Dose: 775 mg, 1 times / day Route: oral Route: steady Dose: 775 mg, 1 times / day Sources: |
unhealthy, > 12 years n = 302 Health Status: unhealthy Condition: pharyngitis secondary to Streptococcus pyogenes Age Group: > 12 years Population Size: 302 Sources: |
| Pharyngolaryngeal pain | severe, 0.6% Disc. AE |
775 mg 1 times / day steady, oral Dose: 775 mg, 1 times / day Route: oral Route: steady Dose: 775 mg, 1 times / day Sources: |
unhealthy, > 12 years n = 302 Health Status: unhealthy Condition: pharyngitis secondary to Streptococcus pyogenes Age Group: > 12 years Population Size: 302 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Amoxicillin caused aseptic meningoencephalitis]. | 1999 Jan 20 |
|
| [Acute renal failure after amoxicillin crystallization]. | 2000 Apr 8 |
|
| Omeprazole-induced delirium. | 2000 Jan |
|
| Amoxicillin plus metronidazole in the treatment of adult periodontitis patients. A double-blind placebo-controlled study. | 2001 Apr |
|
| Efficacy, safety and tolerability of 3 day azithromycin versus 10 day co-amoxiclav in the treatment of children with acute lower respiratory tract infections. | 2001 Apr |
|
| Helicobacter eradication versus prompt endoscopy for dyspepsia. | 2001 Apr |
|
| Simultaneous determination of five beta-lactam antibiotics in bovine milk using liquid chromatography coupled with electrospray ionization tandem mass spectrometry. | 2001 Apr 1 |
|
| Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection. | 2001 Apr 1 |
|
| Comparison of amoxicillin and azithromycin in the prevention of recurrent acute otitis media. | 2001 Apr 6 |
|
| [Eradication therapy of Helicobacter pylori infection]. | 2001 Feb |
|
| Differentiation between reinfection and recrudescence of helicobacter pylori strains using PCR-based restriction fragment length polymorphism analysis. | 2001 Feb |
|
| Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? | 2001 Feb |
|
| Comparison of the efficacy and safety of different formulations of omeprazole-based triple therapies in the treatment of Helicobacter pylori-positive peptic ulcer. | 2001 Feb |
|
| Early stage gastric MALT lymphoma with high-grade component cured by Helicobacter pylori eradication. | 2001 Feb |
|
| Managing pneumonia in general practice. | 2001 Feb |
|
| [Mechanism of drug resistance in Helicobacter pylori]. | 2001 Feb |
|
| [A strategy for second-line anti-Helicobacter pylori therapy in patients with previously failed treatment]. | 2001 Feb |
|
| [Usefulness of new triple therapy containing PPI]. | 2001 Feb |
|
| [Selection of antibiotics and planning of eradication for H. pylori infection]. | 2001 Feb |
|
| [Recent guidelines for the management of Helicobacter pylori infection]. | 2001 Feb |
|
| Free radical production by antibiotic-killed bacteria in the guinea pig middle ear. | 2001 Feb |
|
| Antibiotic-resistance patterns of Helicobacter pylori in Croatia: cohort study. | 2001 Feb |
|
| Two cases of diskitis attributable to anaerobic bacteria in children. | 2001 Feb |
|
| [Prevention of bacterial endocarditis in patients with prosthetic heart valves]. | 2001 Feb 15 |
|
| [Prevalence and treatment of Helicobacter pylori in gastro-duodenal ulcers. An experience in Liege]. | 2001 Jan |
|
| Meropenem in neonatal severe infections due to multiresistant gram-negative bacteria. | 2001 Jan |
|
| A prospective study of antibiotic use and associated infections in young children. | 2001 Jan |
|
| [Prevention of endocarditis within the scope of ENT interventions. Current recommendations]. | 2001 Jan |
|
| [Dilated cardiomyopathy and panuveitis as presenting symptoms of Lyme disease. General review of one case]. | 2001 Jan |
|
| High amoxycillin resistance in Helicobacter pylori isolated from gastritis and peptic ulcer patients in western Nigeria. | 2001 Jan |
|
| A multidisciplinary approach to the diagnosis and treatment of early-onset periodontitis: a case report. | 2001 Jan |
|
| Compliance issues related to the selection of antibiotic suspensions for children. | 2001 Jan |
|
| Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. | 2001 Jan |
|
| Randomized, double-blind, double-dummy study comparing the efficacy and safety of amoxycillin 1 g bd with amoxycillin 500 mg tds in the treatment of acute exacerbations of chronic bronchitis. | 2001 Jan |
|
| Charm Safe-Level beta-Lactam Test for amoxicillin, ampicillin, ceftiofur, cephapirin, and penicillin G in raw commingled milk. | 2001 Jan-Feb |
|
| Clinical onset of the Crohn's disease after eradication therapy of Helicobacter pylori infection. Does Helicobacter pylori infection interact with natural history of inflammatory bowel diseases? | 2001 Jan-Feb |
|
| Eradication of Helicobacter pylori with a metronidazole-containing regimen in a metronidazole-abusing population. | 2001 Jan-Feb |
|
| Standard case management of pneumonia in hospitalized children in Uruguay, 1997 to 1998. | 2001 Mar |
|
| The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication. | 2001 Mar |
|
| Osseintegration following treatment of peri-implantitis and replacement of implant components. An experimental study in the dog. | 2001 Mar |
|
| Lacrimal gland ductal cyst abscess. | 2001 Mar |
|
| Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. | 2001 Mar |
|
| A case of gastric plasmacytoma associated with Helicobacter pylori infection: improvement of abnormal endoscopic and EUS findings after H. pylori eradication. | 2001 Mar |
|
| Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. | 2001 Mar |
|
| [Angina tonsillaris in children. Penicillin V can not be recommended here]. | 2001 Mar 22 |
|
| Activity of moxifloxacin and twelve other antimicrobial agents against 216 clinical isolates of Streptococcus pneumoniae. | 2001 Mar-Apr |
|
| Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. | 2001 May 15 |
Sample Use Guides
In adults, 750-1750 mg/day in divided doses every 8-12 hours. In Pediatric Patients > 3 Months of Age, 20-45 mg/kg/day in divided doses every 8-12 hours. Treatment of gonorrhea is 3 grams as a single oral dose. The upper dose for neonates and infants ≤ 3 months is 30 mg/kg/day divided every 12 hours. Dosing for H. pylori Infection: Triple therapy: 1 gram AMOXIL, 500 mg clarithromycin, and 30 mg lansoprazole, all given twice daily (every 12 hours) for 14 days. Dual therapy: 1 gram AMOXIL and 30 mg lansoprazole, each given three times daily (every 8 hours) for 14 days.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 19:53:17 UTC 2022
by
admin
on
Fri Dec 16 19:53:17 UTC 2022
|
| Record UNII |
804826J2HU
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
A02BD06
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
CFR |
21 CFR 520.88
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
WHO-ATC |
A02BD07
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
WHO-VATC |
QA02BD07
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.2.1 (AMO/CLA)
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
WHO-ATC |
J01CR02
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
WHO-VATC |
QA02BD01
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
NCI_THESAURUS |
C1500
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
CFR |
21 CFR 520.88E
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
WHO-VATC |
QA02BD04
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
CFR |
21 CFR 520.88B
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
WHO-ATC |
A02BD03
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
CFR |
21 CFR 526.88
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
WHO-VATC |
QA02BD05
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
WHO-VATC |
QJ01CA04
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
WHO-ATC |
A02BD10
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.2.1
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
CFR |
21 CFR 520.88H
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
WHO-ATC |
A02BD05
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
WHO-ATC |
J01CA04
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
WHO-VATC |
QJ01CR02
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
CFR |
21 CFR 520.88C
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
WHO-ATC |
A02BD04
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
NDF-RT |
N0000175497
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
WHO-ATC |
A02BD11
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
CFR |
21 CFR 520.88F
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
WHO-VATC |
QG51AA03
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
WHO-VATC |
QA02BD03
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
CFR |
21 CFR 520.88A
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
LIVERTOX |
NBK547854
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
CFR |
21 CFR 520.88G
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
WHO-VATC |
QA02BD06
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
WHO-VATC |
QJ51CR02
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
CFR |
21 CFR 556.38
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
CFR |
21 CFR 522.88
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
WHO-ATC |
A02BD01
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
||
|
CFR |
21 CFR 520.88D
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
723
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
ALTERNATIVE | |||
|
51254
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
PRIMARY | |||
|
D000658
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
PRIMARY | |||
|
Amoxicillin and Clavulanic Acid
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
PRIMARY | |||
|
Amoxicillin
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
PRIMARY | |||
|
DB01060
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
PRIMARY | |||
|
1031503
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
PRIMARY | |||
|
DTXSID2022599
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
PRIMARY | |||
|
804826J2HU
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
PRIMARY | |||
|
CHEMBL1082
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
PRIMARY | |||
|
C237
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
PRIMARY | |||
|
M1844
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
PRIMARY | Merck Index | ||
|
AMOXICILLIN
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
PRIMARY | Description: A white or almost white, crystalline powder; odourless. Solubility: Slightly soluble in water and methanol R; very slightly soluble in ethanol (~750 g/l) TS, ether R, and fatty oils; soluble in dilute acids and dilute solutions of alkali hydroxides. Category: Antibacterial drug. Storage: Amoxicillin trihydrate should be kept in a tightly closed container. Requirement: Amoxicillin trihydrate contains not less than 95.0% and not more than the equivalent of 102.0% of C16H19N3O5S, calculated with reference to the anhydrous substance. | ||
|
61336-70-7
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
PRIMARY | |||
|
804826J2HU
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
PRIMARY | |||
|
SUB00504MIG
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
PRIMARY | |||
|
AMOXICILLIN
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
PRIMARY | |||
|
62883
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
PRIMARY | |||
|
133008
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
PRIMARY | |||
|
192
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
PRIMARY | |||
|
2676
Created by
admin on Fri Dec 16 19:53:17 UTC 2022 , Edited by admin on Fri Dec 16 19:53:17 UTC 2022
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
EP
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
BINDER->LIGAND |
BINDING
|
||
|
ANHYDROUS->SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
TRANSPORTER -> SUBSTRATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT | |||
|
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Biological Half-life | PHARMACOKINETIC |
|
EXTENDED-RELEASE DOSE PHARMACOKINETIC |
|
||
| Volume of Distribution | PHARMACOKINETIC |
|
|
|||
| Tmax | PHARMACOKINETIC |
|
ORAL EXTENDED-RELEASE DOSE PHARMACOKINETIC |
|
||